ArticleJournal of psychopharmacology (Oxford, England)2023
Risks and benefits of psilocybin use in people with bipolar disorder: An international web-based survey on experiences of 'magic mushroom' consumption.
Article in Journal of psychopharmacology (Oxford, England), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 3 syntheses or guidelines pooled it, 67 citations in OpenAlex.
- Psychedelic-induced hypomania and mania: a systematic review and meta-analysis.Molecular psychiatry · 2026Pooled it
- Multilevel Mechanisms and Clinical Efficacy of Psilocybin in Depression Treatment: A Systematic Review.International journal of molecular sciences · 2026Pooled it
- Reconsidering evidence for psychedelic-induced psychosis: an overview of reviews, a systematic review, and meta-analysis of human studies.Molecular psychiatry · 2025Pooled it
- Article
- Naturally Derived Psilocybin for Therapeutic Use: A Six-Criterion Framework for Evidence, Safety, and Benefit-Risk Considerations in Policy and Clinical Development.Biomolecules · 2026Review
- Psilocybin and Bipolar Depression: Promise and Prudence.CNS drugs · 2026Review
- 5 Years of bipolar disorder conversations on Reddit: Methods, key topics and future directions.PloS one · 2026Article
- Review
- The Emergence of Psilocybin in Psychiatry and Neuroscience.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Longitudinal associations of naturalistic psychedelic use with psychotic and manic symptoms.Psychological medicine · 2025Observational
- Psilocybin-Assisted Psychotherapy for Treatment-Resistant Depression in Bipolar II Disorder.Psychedelic medicine (New Rochelle, N.Y.) · 2025Article
- Prolonged adverse effects from repeated psilocybin use in an underground psychedelic therapy training program: a case report.BMC psychiatry · 2025Article
- Article
- Roadmap for Equitable Access and Responsible Use of Psilocybin-Assisted Psychotherapy in Palliative Care.Palliative medicine reports · 2025Article
- Characteristics and mental health of psychedelic mushroom and multi-psychedelic users relative to non-psychedelic users in American adults, 2020-2021.Frontiers in psychiatry · 2025Article
- A Plea for Nuance: Should People with a Family History of Bipolar Disorder Be Excluded from Clinical Trials of Psilocybin Therapy?Psychedelic medicine (New Rochelle, N.Y.) · 2024Review
- Longitudinal associations between psychedelic use and psychotic symptoms in the United States and the United Kingdom.Journal of affective disorders · 2024Article
- Striking the Balance: Bipolar Disorder in the Perinatal Period.Focus (American Psychiatric Publishing) · 2024Review
- Manic episode following psilocybin use in a man with bipolar II disorder: a case report.Frontiers in psychiatry · 2023Article
- Article
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
6 authors at 3 institutions in 2 countries.
Funding
Abstract
backgroundPsilocybin, the primary psychoactive component of psychedelic 'magic mushrooms', may have potential for treating depressive symptoms, and consequent applications for bipolar disorder (BD). Knowledge of the risks and benefits of psilocybin in BD is limited to case studies.
aimTo support the design of clinical trials, we surveyed experiences of psilocybin use in people with BD.
methodsAn international web-based survey was used to explore experiences of psilocybin use in people with a self-reported diagnosis of BD. Quantitative findings were summarised using descriptive statistics. Qualitative content analysis was used to investigate free-text responses, with a focus on positive experiences of psilocybin use.
resultsA total of 541 people completed the survey (46.4% female, mean 34.1 years old). One-third (32.2%;
conclusionsThe subjective benefits of psilocybin use for mental health symptoms reported by survey participants encourage further investigation of psilocybin-based treatments for BD. Clinical trials should incorporate careful monitoring of symptoms, as data suggest that BD symptoms may emerge or intensify following psilocybin use.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.